Skip to main content
Premium Trial:

Request an Annual Quote

AB Sciex, Premier Biosoft Partner on Lipidomic Software

NEW YORK (GenomeWeb News) – Premier Biosoft today announced a co-marketing and reselling deal with AB Sciex for lipidomic research software.

Under the terms of the deal, AB Sciex, a Danaher company, will co-market and resell Premier's SimLipid, a high-throughput lipid identification software product, for use with AB Sciex's mass spectrometers.

SimLipid profiles lipids in samples by doing a precursor search for mass spec data and provides structural information by matching product ions observed on MS/MS spectra. According to Premier, the software can be used for analyzing both low-resolution and high-resolution data.

"Combining AB Sciex's mass spectrometery data with SimLipid creates an opportunity for researchers to gain access to unparalleled information for lipid characterization," Premier President Kay Brown said in a statement.

Financial and other terms of the deal were not disclosed.

In 2008 Premier and AB Sciex, which at the time was part of Applied Biosystems, collaborated on the development of integrated workflows for glycomics research.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.